Previous analysis showed that a more aggressive and active disease state with high tumor burden often could improve the positive detected rate of MET amplification by liquid biopsy, because this assay relies on sufficient levels of circulating tumor DNA (ctDNA) shed by tumors (Mazieres et al., 2023). The gene discussed is MET; the disease is neoplasm.